Skip to main content

RETRACTED ARTICLE: Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults’ age groups and their association with prediction of poor prognosis in human osteosarcoma

Tumor Biology volume 37, pages 3091–3095 (2016)Cite this article

This article was retracted on 05 November 2016

Abstract

Osteosarcoma is the most common type of bone cancer in children and adolescents. MicroRNAs (miRNAs) play important roles in the development, differentiation, and function of different cell types and in the pathogenesis of various human diseases. miRNAs are differentially expressed in normal and cancer cells. The investigation of miRNA expression between healthy subjects and patients with osteosarcoma is crucial for future clinical trials. In this study, the expression levels of miRNAs were detected by qRT-PCR. Correlation between expression levels of tow miRNAs and different clinicopathological characteristics were analyzed using the χ 2 test. Survival rate was detected using the log-rank test and Kaplan–Meier method. qRT-PCR was shown that expression levels of miR-29b and miR-422a were strongly decreased in osteosarcoma bone tissue compared with noncancerous bone tissues. Our result indicated that the low expression levels of miR-29b and miR-422a showed strong correlation with large tumor size (P = 0.20; 0.029), advanced TNM stage (P = 0.001; 0.012), distant metastasis (P = 0.008; 0.019), and grade of tumor (P = 0.009; 0.016). Kaplan–Meier survival analysis showed that the low expressions of miR-29b/miR-422a were correlated with shorter time overall survival (log-rank test, P = 0.009; P = 0.013). Moreover, multivariate Cox proportional hazards model indicated that miR-29b and miR-422a (P = 0.024; P = 0.016) were independent prognostic markers of overall survival of patients. Our result indicated that downregulation of miR-29b and miR-422a may be linked to the prediction of poor prognosis, indicating that miR-29b and miR-422a may be a valuable prognostic marker for osteosarcoma patients.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.

    Article  PubMed  Google Scholar 

  2. Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma. 2011;2011:959248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Leary SE, Wozniak AW, Billups CA, Wu J, McPherson V, Neel MD. Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children’s Research Hospital experience. Cancer. 2013;119(14):2645–53.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. Kager L, Zoubek A, Kastner U, Kempf-Bielack B, Potratz J, Kotz R. Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2006;24(10):1535–41.

    Article  PubMed  Google Scholar 

  5. Henry JC, Park JK, Jiang J, Kim JH, Nagorney DM, Roberts LR, et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010;403:120–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. Baumhoer D, Zillmer S, Unger K, Rosemann M, Atkinson MJ, Irmler M. MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma. Cancer Genet. 2012;205(5):212–9.

    CAS  Article  PubMed  Google Scholar 

  7. Jin J, Cai L, Liu ZM, Zhou XS. miRNA-218 Inhibits osteosarcoma cell migration and invasion by down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev. 2013;14(6):3681–4.

    Article  PubMed  Google Scholar 

  8. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ. miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 2012;72(7):1865–77.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Sun Y, Fang R, Li C, Li L, Li F, Ye X. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun. 2010;396(2):501–7.

    CAS  Article  PubMed  Google Scholar 

  10. Kwiecinski M, Elfimova N, Noetel A, Tox U, Steffen HM, Hacker U, et al. Expression of platelet-derived growth factor-c and insulin-like growth factor i in hepatic stellate cells is inhibited by miR-29. Lab Invest. 2012;92:978–87.

    CAS  Article  PubMed  Google Scholar 

  11. Dai N, Zhong ZY, Cun YP, Qing Y, Chen C, Jiang P, et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma. 2013;60:384–94.

    CAS  Article  PubMed  Google Scholar 

  12. Hong Q, Fang J, Pang Y. Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 2014;31:37.

    Article  CAS  PubMed  Google Scholar 

  13. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2011;129:680–90.

    CAS  Article  PubMed  Google Scholar 

  14. Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. MiR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma. Asian Pac J Cancer Prev. 2013;14:885–9.

    Article  PubMed  Google Scholar 

  15. Zhao G, Cai C, Yang T. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 2013;8(1):e53906.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Huang J, Gao K, Lin J. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumor Biol. 2014;35(2):1095–100.

    CAS  Article  Google Scholar 

  17. Sandhu R, Rivenbark AG, Mackler RM, Livasy CA, Coleman WB. Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. Int J Oncol. 2014;44:563–72.

    CAS  PubMed  Google Scholar 

  18. Cheng J, Guo S, Chen S. An extensive network of TET2-targeting microRNAs regulates malignant hematopoiesis. Cell Rep. 2013;5(2):471–81.

    CAS  Article  PubMed  Google Scholar 

  19. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med. 2012;16:2655–66.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. Yan B, Guo Q, Fa-jun F, Wang Z, Yin Z, Wei Y-b, et al. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 2015;8:539–48.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We wish to thank Dr. Javanbakht for attentive English language editing of our manuscript.

Conflicts of interest

None

Author information

Affiliations

  1. Department of Orthopaedic and Trauma Surgery, Birjand University of Medical Sciences, Birjand, Iran

    Reza Bahador & Mohammadreza Shakeri

  2. Department of Orthopedics Surgery, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran

    Afshin Taheriazam

  3. Department of Orthopedics, Qom University of Medical Sciences, Qom, Iran

    Alireza Mirghasemi

  4. Department of Orthopedics, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran

    Ali Torkaman

  5. Department of Molecular Biology, Baqiyatallah University of Medical Sciences, Tehran, Iran

    Emad Yahaghi

  6. Department of Neurosurgery, AJA University of Medical Sciences, Tehran, Iran

    Peyman Karimi Goudarzi

Authors
  1. Reza Bahador
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Afshin Taheriazam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alireza Mirghasemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ali Torkaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammadreza Shakeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emad Yahaghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peyman Karimi Goudarzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peyman Karimi Goudarzi.

Additional information

This article has been retracted at the request of the Editor-in-Chief, the International Society of Oncology and BioMarkers (ISOBM) and the Publisher per the Committee on Publication Ethics guidelines. The article shows evidence of irregularities in authorship, there is strong reason to believe that the peer review process was compromised and the article is showing similarities with the following article which was submitted within a close timeframe:

Seyad Alireza Bassampour, Reza Abdi, Reza Bahador, Mohammadreza Shakeri, Ali Torkaman, Emad Yahaghi, Afshin Taheriazam, Downregulation of miR-133b/miR-503 acts as efficient prognostic and diagnostic factors in patients with osteosarcoma and these predictor biomarkers are correlated with overall survival. Tumor Biol. First online: 16 August 2015 DOI: 10.1007/s13277-015-3918-9

Date received: 20 July 2015

The retracted article was received: 8 August 2015.

As such the validity of the content of this article cannot be verified.

An erratum to this article is available at http://dx.doi.org/10.1007/s13277-016-5480-5.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bahador, R., Taheriazam, A., Mirghasemi, A. et al. RETRACTED ARTICLE: Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults’ age groups and their association with prediction of poor prognosis in human osteosarcoma. Tumor Biol. 37, 3091–3095 (2016). https://doi.org/10.1007/s13277-015-4140-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4140-5

Keywords

  • miR-29b and miR-422a
  • Survival
  • PCR
  • Osteosarcoma
  • Pathology